Consequently, we recommend initiating public initiatives to improve ALK diagnostics in NSCLC, to optimize the subsequent therapy, and to focus on the best available treatment options, even if it may not be a newly available drug. This evidence concerns the gene ALK and non-small cell lung carcinoma.